Join
Live feed
·
INSIDERFilingvia Quantisnow
Anika Therapeutics Inc. logo

Director Henneman John B Iii bought $73,320 worth of shares (5,000 units at $14.66), increasing direct ownership by 10% to 54,871 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ANIK· Anika Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANIK (Anika Therapeutics Inc.) and more on Quantisnow.